FDA WARNING_LETTER - Sigel Cattle Company, Inc. - June 10, 2025

The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Ogle Cattle Company, Inc. on September 05, 2025, following inspections conducted on April 17, 18, May 6, and June 10, 2025. The letter details significant violations of the Federal Food, Drug, and Cosmetic Act concerning animal drug use and food safety.

The primary violation involved the adulteration of animals offered for human consumption. Four cattle sold for slaughter were found to have desfuroylceftiofur (ceftiofur drug residue) in their kidney tissue at levels significantly exceeding the FDA"s established tolerance of 0.4 parts per million (ppm), ranging from 0.520 ppm to 9.44 ppm. This indicates inadequate controls, as the company failed to maintain identity and treatment records for medicated animals, and did not segregate them, creating conditions where drug-adulterated food animals could enter the food supply.

Additionally, the company was cited for the adulteration of an animal drug due to its improper extralabel use. Ogle Cattle Company, Inc. administered a ceftiofur class drug to cattle via an unapproved subcutaneous injection route, despite the product"s label specifying a different method. Such extralabel use is strictly prohibited in food-producing animals without the oversight of a licensed veterinarian within a valid veterinarian-client-patient relationship, rendering the drug unsafe.

The FDA requires Ogle Cattle Company, Inc. to submit a written response within fifteen working days. This response must detail the specific steps taken to correct all violations, explain measures to prevent their recurrence, and include supporting documentation. Failure to adequately address these concerns may lead to further legal action, including seizure and injunction.